These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 18826864)

  • 1. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.
    Genser B; Grammer TB; Stojakovic T; Siekmeier R; März W
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):497-510. PubMed ID: 18826864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.
    Ndrepepa G; Braun S; Tada T; Guerra E; Schunkert H; Laugwitz KL; Kastrati A
    Cardiovasc Revasc Med; 2014 Apr; 15(3):131-6. PubMed ID: 24630704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials.
    Arabi SM; Chambari M; Malek-Ahmadi M; Bahrami LS; Hadi V; Rizzo M; Sahebkar A
    Inflammopharmacology; 2022 Oct; 30(5):1597-1615. PubMed ID: 35988111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of statin therapy in maintenance dialysis patients.
    Sun L; Zou L; Chen M; Liu B
    Ren Fail; 2015 Aug; 37(7):1149-56. PubMed ID: 26139229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level.
    Yamawaki T; Yamada A; Fukumoto Y; Kishi T; Sobashima A; Kuwata K; Nakamura R; Sekiya M; Ando H; Okamatsu S
    Fukuoka Igaku Zasshi; 2007 Jun; 98(6):260-9. PubMed ID: 17665547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome.
    Fang M; Qian Q; Zhao Z; Zhu L; Su J; Li X
    Int Heart J; 2018 Mar; 59(2):300-306. PubMed ID: 29479010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.